load and high CD4 counts and generally in good health. The researchers concluded that although most of the lost patients were at no immediate health risk to themselves, they might be at risk of transmitting the virus to others.
Are protease inhibitors stronger?
Protease inhibitors (PIs) may be more effective than non-nucleoside drugs (NNRTIs) at driving down HIV replication to very low levels, the 8th BHIVA Conference was told. Dr John Morlese of Chelsea and Westminster Hospital measured 'LTR circles', a waste product of HIV replication in the cells of HIV positive patients. Their presence indicates continuing low-level viral replication, and patients treated with PI-based regimes had fewer than those on NNRTI-based regimes.
Gilead told off for tenofovir plug
The drug firm Gilead has been told off for over-enthusiastic marketing statements about its new anti-HIV drug tenofovir - brand name Viread. The US Food and Drug Agency criticised Gilead reps for telling the ICAAC Conference last December that Viread had 'no toxicities', despite the drug's product label warning of possible complications such as the rare but life-threatening side effect, lactic acidosis. Gilead said they were trying to identify the company reps who had made the 'no toxicity' claim, but pointed out that tenofovir, unlike the other nucleoside drugs to which it is similar, does not damage the energy-producing components of cells, which causes lactic acidosis.
True non-progressors 'rare'

page 8 of 9

1 / 2 / 3 / 4 / 5 / 6 /
7 / 8 / 9

home

contents of issue 79
back issues
the gazette
recipes
small ads
contacting us
weblinks

A study says that long-term non-progressors (LTNPs) - people with HIV who